Hims & Hers Health (NYSE:HIMS) stock fell 5% in after-hours trading on Thursday following a Bloomberg report that revealed ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Consumer demand for GLP-1 drugs like Ozempic and Wegovy has drawn a flood of new entrants. Yaccarino will have to find a way ...

Justin Penik gives his thoughts and observations from the Giants-Jets joint practice. 00:00 Giants vs jets Practice Recap ...

While Wall Street analysts remain cautious on Hims & Hers Health ($HIMS), TipRanks’ A.I. Stock Analysis tool shows strong ...

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

In Q2 2025, Hims & Hers reported adjusted earnings of $0.17 per share, topping estimates of $0.15. Revenue rose 73% year-over ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...